The Fascinating Dance Between Your Gut Microbiome and GLP-1

Introduction: The Dynamic Duo – GLP-1 and the Microbiome

Picture a potent hormone named GLP-1 and a bustling metropolis of microorganisms known as the microbiome. GLP-1, or Glucagon-like peptide-1, is a maestro in the world of glucose metabolism, conducting the symphony of insulin secretion, glucagon release, and gastric emptying to maintain our post-meal blood sugar levels.

The microbiome, on the other hand, is a vibrant city within us, teeming with bacteria, fungi, viruses, and archaea. The gut, the heart of this city, houses the largest and most diverse population. These microbial citizens aid in digestion, synthesize vitamins, and train our immune system  (1).

Our gut microbiota can sway the secretion of GLP-1. Certain bacterial species stimulate our L cells, specialized cells nested in the gut lining, to produce more GLP-1, thereby influencing our metabolic health and blood glucose levels. For example, a high-fiber diet can boost the population of bacteria that produce short-chain fatty acids (SCFAs), which trigger the release of GLP-1 (1).

GLP-1 also acts as a peacekeeper, having anti-inflammatory effects that can influence the composition of the gut microbiota. It can reduce gut permeability, preventing endotoxins from escaping into the bloodstream and triggering inflammation. This interaction highlights the intricate interplay between GLP-1, the gut microbiota, and inflammation (1).

There are several strategies to bolster the dialogue between the gut microbiota and GLP-1. Prebiotics and probiotics can improve gut health and stimulate GLP-1 secretion. Antidiabetic drugs, like metformin, can modify the gut microbiota composition and elevate GLP-1 levels. Even bariatric surgery can alter the gut microbiota and enhance GLP-1 response  (1).

A key player in this dialogue is a class of drugs used in the treatment of type 2 diabetes, known as GLP-1 receptor agonists. GLP-1 receptor agonists offer several advantages that make them a preferred choice for certain individuals over other antidiabetic drugs. They mimic the function of the body’s natural GLP-1 hormone, which helps regulate blood sugar levels by stimulating insulin secretion, inhibiting glucagon release, and slowing gastric emptying. This makes them particularly effective in managing post-meal blood sugar spikes. Additionally, GLP-1 receptor agonists have been shown to promote weight loss, a common challenge for individuals with type 2 diabetes. Lastly, these drugs have a lower risk of causing hypoglycemia compared to some other antidiabetic medications. However, it’s crucial to note that the effectiveness of GLP-1 receptor agonists can vary among individuals due to the unique composition of their gut microbiota. Therefore, a personalized approach, considering the individual’s microbial composition, can help optimize the efficacy of these drugs (1-3).

The uniqueness of the microbiome may result in individualized responses to GLP-1 drugs. A mechanistic understanding of the role of the microbiota in diseases and GLP-1 drug metabolism would help us identify causal relationships and thus guide the development of microbiome-based precision or personalized medicine. It’s akin to understanding the nuances of each dancer’s style and using that knowledge to choreograph a dance that is both beautiful and effective  (6).

For example, common medications can change the way our gut bacteria respond to the vitamins and minerals we consume. Therefore, by understanding these interactions, we can tailor the right GLP-1 drugs based on the individual’s microbial composition. It’s like adjusting the choreography to match the dancer’s style, creating a dance that is both unique and effective (7-8).

At DayTwo, we’re active participants in the dance between GLP-1 and the gut microbiota. We have a vast dataset of full-shotgun sequenced gut microbiome samples, backed by electronic medical records. We can see how different drugs influence this dance, providing valuable insights for personalized medicine. Furthermore, it allows us to correlate microbial composition and function with various health outcomes. This can reveal new connections and deepen our understanding of the role of the microbiome in health and disease.

The following plot demonstrates the decrease in glycated hemoglobin (Hba1c(%)) levels of DayTwo users taking GLP-1 receptor agonist drugs compared to those on other antidiabetic medications. Statistical tests confirm the significance of these results. Intriguingly, the reduction is comparable for both medication types. This implies that GLP-1 receptor agonists are equally effective as other antidiabetic medications in lowering glycated hemoglobin levels, a crucial indicator of long-term blood glucose control.

Moreover, the unique blend of gut bacteria in individuals treated with GLP-1 receptor agonists versus those on other antidiabetic medications provides a fascinating glimpse into the microbiome’s role in drug response. The diagrams below compare the levels of specific bacteria between the two groups, emphasizing this point. These statistically significant findings depict the microbial signatures that differ between patients on GLP-1 receptor agonists and those on other antidiabetic medications. This could potentially underscore the impact of these medications on the gut microbiome, offering additional insight into their mechanisms of action and their influence on metabolic health.

These findings could guide the development of more effective treatment strategies, tailored to the individual’s microbial composition. It’s akin to tailoring the choreography to suit the dancer’s style, crafting a distinctive and effective dance. This dance of personalized medicine, guided by our understanding of the microbiome, harbors immense potential for the future of healthcare.

As we continue to explore the intricate dance between GLP-1 drugs and the gut microbiota, we are constantly learning new steps and discovering new rhythms. The dance floor of personalized medicine is vast and full of potential. With every discovery, we move closer to a future where every individual has a dance choreographed just for them, a future where medicine is as unique as the individual it serves. And at DayTwo, we’re proud to be part of this exciting journey. 

  1. Zeng, Y., Wu, Y., Zhang, Q., & Xiao, X. (2024). Crosstalk between glucagon-like peptide 1 and gut microbiota in metabolic diseases. Mbio, 15(1), e02032-23.
  2. Madsen, M. S. A., Holm, J. B., Pallejà, A., Wismann, P., Fabricius, K., Rigbolt, K., … & Hansen, H. H. (2019). Metabolic and gut microbiome changes following GLP-1 or dual GLP-1/GLP-2 receptor agonist treatment in diet-induced obese mice. Scientific reports, 9(1), 15582.
  3. Tsai, C. Y., Lu, H. C., Chou, Y. H., Liu, P. Y., Chen, H. Y., Huang, M. C., … & Tsai, C. N. (2022). Gut microbial signatures for glycemic responses of GLP-1 receptor agonists in type 2 diabetic patients: a pilot study. Frontiers in Endocrinology, 12, 814770.
  4. Roume, H., Mondot, S., Saliou, A., Le Fresne-Languille, S., & Doré, J. (2023). Multicenter evaluation of gut microbiome profiling by next-generation sequencing reveals major biases in partial-length metabarcoding approach. Scientific Reports, 13(1), 22593.
  5. Shen, Y., Qian, Q., Ding, L., Qu, W., Zhang, T., Song, M., … & Wang, Y. (2024). High-throughput single-microbe RNA sequencing reveals adaptive state heterogeneity and host-phage activity associations in human gut microbiome. Protein & Cell, pwae027.
  6. Petrosino, J. F. (2018). The microbiome in precision medicine: the way forward. Genome medicine, 10, 1-4.
  7. Pryszlak, A., Wenzel, T., Seitz, K. W., Hildebrand, F., Kartal, E., Cosenza, M. R., … & Merten, C. A. (2022). Enrichment of gut microbiome strains for cultivation-free genome sequencing using droplet microfluidics. Cell Reports Methods, 2(1).
  8. Noh, K., Kang, Y. R., Nepal, M. R., Shakya, R., Kang, M. J., Kang, W., … & Jeong, T. C. (2017). Impact of gut microbiota on drug metabolism: an update for safe and effective use of drugs. Archives of Pharmacal Research, 40, 1345-1355.
Ready to get started?
Get in touch